MB-105 in Patients with CD5 Positive Relapsed/Refractory T-Cell Lymphoma

The purpose of this study is to find out how safe and effective a new CAR-T study treatment, called MB-105, is for people with T-cell lymphoma. MB-105 is an experimental study treatment. This means it is not approved for general use by the U.S. Food and Drug Administration (FDA) and, as such, can only be used in research studies.